OncoMatch/Clinical Trials/NCT06515613
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Is NCT06515613 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CTIM-76 for platinum-resistant ovarian cancer.
Treatment: CTIM-76 — This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Testicular Germ Cell Tumor
Endometrial Cancer
Biomarker criteria
Required: CLDN6 positive
CLDN6 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arkansas Winthrop P. Rockefeller Cancer Institute · Little Rock, Arkansas
- Precision NextGen Oncology & Research Center · Beverly Hills, California
- SCRI at Denver Health · Denver, Colorado
- Dana-Farber Cancer Institute · Boston, Massachusetts
- John Theurer Cancer Center · Hackensack, New Jersey
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify